BioCentury
ARTICLE | Distillery Therapeutics

Autoimmune disease

May 1, 2018 11:27 PM UTC

Mouse studies identified a peptide-based GLP-2R activator that could help treat IBD. Chemical synthesis and testing in a cell-based activity assay of GLP-2-based stapled peptides yielded a peptide that activated GLP-2R with an EC50 of 28 pM. In a mouse model of IBD, the peptide increased body weight and small intestine weight and length compared with vehicle. Next steps could include testing the peptide in additional models of IBD.

Shire plc markets Gattex teduglutide, an analog of GLP-2 targeting GLP-2R, to treat short bowel syndrome (SBS), and has the compound in Phase II testing to treat Chron's disease...